Sign up


Match Document Document Title
9011929 Composition for inducing tissue regeneration by activating platelet-rich plasma (PRP)  
The present invention relates to a composition for cartilaginous tissue repair and to a production method therefor. The present invention comprises the steps of: (a) dissolving freeze-dried...
9012406 Light activated composite tissue adhesives  
Disclosed herein are compositions comprising gelatin, collagen, and a chromophore that produces a reactive oxygen species upon exposure to electromagnetic radiation. These compositions have also...
9012407 Therapies which act on neuropeptide S receptors  
Compositions and methods that act on Neuropeptide S receptors (NPSR) (also known as “TGR23” or “vasopressin receptor-related receptor 1 (VRR1)”) to cause desired effects in the bodies of human o...
9011862 Inhibitors of the nitration of amyloid β peptides and their uses in the diagnosis and treatment of Alzheimer's disease  
The present invention relates to a method for identifying an inhibitor of the aggregation of amyloid-β peptide (Aβ), comprising the steps of a) contacting at least one Aβ -peptide and/or the ni...
9006193 Polymeric carrier  
Provided herein are polymeric carriers suitable for the delivery of polynucleotides (e.g. oligonucleotides) and/or other therapeutic agents into a living cell.
9006182 Light activated composite tissue adhesives  
A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions. These composites have also been found to be strong tissue adheives that are...
9006205 Antisense oligonucleotides against neutral sphingomyelinase and neutral sphingomyelinase inhibitor GW4869 for degenerative neurological disorders  
Alzheimer's disease (AD) is the most common human neurodegenerative disease of the CNS resulting in progressive neuronal death and memory loss. Despite intense investigations, no effective therapy...
8999927 Glial cell line-derived neurotrophic factor (GDNF) compositions and use thereof  
Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided...
8999937 Glucocorticoid induced leucine zipper mimetics as therapeutic agents in multiple sclerosis  
Polypeptide compositions that mimic the activity of glucocorticoid induced leucine zipper (GILZ) on the immune system are described. Also described is a method of treating multiple sclerosis using...
8999936 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof  
The invention relates to an isolated monoclonal antibody or antigen-binding fragment thereof that (a) binds (i) wild-type Aβ 42/40 protofibril comprising N-terminal truncated Aβ forms and (ii) A...
8999338 Method for diagnosis for multiple sclerosis involving anti1-receptor antibody  
The invention relates to a method for diagnosis of multiple sclerosis (MS) wherein, presence or absence of an anti-AT1 receptor antibody is determined in a sample from a patient to be diagnosed and...
8993721 Peptides for targeting apoptotic cells and uses thereof  
Described herein is an isolated polypeptide which is capable of specifically targeting apoptotic cells undergoing apoptosis and consists of the sequence (I): Cys-X1-Val-Ala-Pro-X2 (I), wherein X1...
8987207 Peptides which have analgesic effects and which inhibit ASIC channels  
Novel isolated peptides which induce analgesia and which inhibit ASIC channels (Acid Sensing Ion Channels), to the polynucleotides encoding these peptides, and also to the pharmaceutical...
8987205 Polynucleotides encoding recombinant lubricin molecules and uses thereof  
Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial...
8987201 Black bear parathyroid hormone and methods of using black bear parathyroid hormone  
Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming...
8987208 Botulinum neurotoxin a receptor and the use thereof  
The present invention is based on the identification of synaptic vessel glycoprotein SV2 as the BoNT/A receptor and the further identification of various BoNT/A-binding fragments of SV2. The...
8987206 Method of treating attention deficit hyperactivity disorder  
The present invention relates to a method of treating attention deficit hyperactivity disorder (ADHD) and attention deficit disorder (ADD) by administration of activated-potentiate form of...
8987199 Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders  
In one embodiment of the invention, a pharmaceutical composition for intranasal administration comprises insulin, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. In...
8986690 Modulation of activity of neurotrophins  
The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and...
8987211 Therapeutic peptides and use thereof against huntington's disease  
Fusion proteins that contain the fusion of (i) a peptide of less than 100 amino acids comprising a first amino acid sequence comprising AASSG (SEQ ID NO: 1) and a second amino acid sequence...
8980836 Method of treating degenerative disorders of the nervous system  
The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise administration of antibodies directed towards peptides that bind to receptors...
8980271 Methods of treating a tauopathy  
The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising...
8980835 Chemically modified water-soluble elastin, mixed gel of chemically modified water-soluble elastin and collagen, and process for producing same  
A chemically modified water-soluble elastin that is obtained by subjecting to N-acylating some or all of the primary amines and secondary amines contained in the molecule of a high molecular weight...
8980270 Methods of treating a tauopathy  
The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising...
8980250 Use of des-aspartate-angiotensin I in inflammation-related pathologies and diseases  
The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of...
8974782 Treatment of stroke comprising anti-MAG antibodies  
The present invention relates to a dosing regimen for use in the treatment of stroke. More particularly, the invention relates to the administration of two doses of anti-MAG antibodies for the...
8974791 Methods and compositions for increasing α-L-iduronidase activity in the CNS  
Provided herein are methods and compositions for treating a subject suffering from a deficiency in α-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion ...
8975233 Methods for renal denervation  
Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the...
8968716 In situ-forming hydrogel for tissue adhesives and biomedical use thereof  
Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over...
8969301 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases  
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use...
8969295 Identifying and modulating molecular pathways that mediate nervous system plasticity  
The present invention provides methods for identifying genes and pathways involved in plasticity. The invention applies some of these methods to identify genes that are differentially regulated in...
8968734 Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's disease, dementia with lewy bodies and other α-synucleinopathies  
Antibodies and fragments thereof have high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers, wherein the antibodies or fragments have specified Complementarity D...
8969302 Low frequency glatiramer acetate therapy  
A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first...
8969077 Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord  
The invention provides an expression system for producing Caveolin-1 in neuronal cells or neural stem cells comprising a neuron-specific regulatory element and a nucleic acid sequence encoding...
8961986 Peptide composition  
There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also provided...
8961929 Targeting agent for tumor site  
It is an object of the present invention to provide a targeting agent, which enables the delivery of a drug to tumor sites or the imaging of tumor sites by utilizing its effect of accumulating to...
8961981 Targeting the neuromuscular junction for treatment  
Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular...
8962564 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity  
Described herein are variant, recombinant β-glucocerebrosidase proteins characterized as having increased stability relative to recombinant wild-type β-glucocerebrosidase. Also provided herein a...
8957030 Methods for preventing or treating mitochondrial permeability transition  
The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at...
8957050 Bone implant materials comprising cross-linked bioactive hydrogel matrices  
The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently...
8951968 Methods of treating depression and other related diseases  
The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist.
8951969 Compositions and methods for treating centrally mediated nausea and vomiting  
Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
8945576 Vaccine for treatment of tautopathy  
This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a...
8945535 Implant for the repair of a cartilage defect and method for manufacturing the implant  
For the repair of a cartilage defect in a human or animal patient use is made of an implant comprising an implant body including a natural cartilage matrix and being coated with cells having a...
8946164 Bioactive peptide  
The present invention provides a pharmaceutical or a food that comprises, as an active ingredient, at least one peptide selected from the group consisting of Val-Tyr-Leu-Pro-Arg (SEQ ID NO:1),...
8946165 Compounds for reversing and inhibiting protein aggregation, and methods for making and using them  
The invention provides compositions for increasing the clearance of protein aggregates, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for...
8945586 Therapeutic use of the encoding sequence of the carboxy-terminal domain of the heavy chain of the tetanus toxin  
The present invention relates to the therapeutic use of the carboxy-terminal domain of the heavy chain of the tetanus toxin for the treatment of amyotrophic lateral sclerosis (ALS).
8945600 Methods of delivering pharmaceutical agents  
Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include...
8946151 Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen  
A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to one or both putamen of a human in...
8946163 Cross-linked collagen comprising metallic anticancer agents  
The disclosure describes collagen constructs comprising anticancer agents, preferably, platinum, and related methods.